Hong Kong's Insilico Raises $255 Million for AI Drug Discovery/R&D
June 22, 2021 at 05:42 AM EDT
Insilico Medicine, a Hong Kong company devoted to using AI to speed up drug discovery and R&D, closed a $255 million Series C round led by Warburg Pincus. Insilico has said its platforms identified a completely novel target for idiopathic pulmonary fibrosis and designed a novel molecule in 18 months for only $2 million. The company is developing its own products and has also formed discovery/development partnerships with well-known pharmas. Several of these programs have reached major milestones, Insilico said. More details.... Share this with colleagues: // //
